Discussions on the groundbreaking ABRUPT trial for prostate cancer
The ABRUPT Trial aimed to assess late GI and GU side effects in patients with organ-confined unfavourable prostate cancer (PCa) treated with single-dose ablative radiotherapy (SDRT).
Authors: Stefano Arcangeli, Chiara Chissotti, Federica Ferrario, Raffaella Lucchini, Maria Belmonte, Giorgio Purrello, Riccardo Ray Colciago, Elena De Ponti, Valeria Faccenda, Denis Panizza
Stefano Arcangeli, Radiation Oncologist and Associate Professor at University of Milan Bicocca, shared his thought on X:
“Our paper on first shot RT for UIR and HR prostate cancer is finally out on IJROBP. Kudos to the authors for the team effort!”
Valeria Faccenda, Medical Physicist at Fondazione IRCCS San Gerardo dei Tintori Monza (Italy), replied:
“Encouraging preliminary results from ABRUPT trial on 24Gy single fraction RT to the prostate gland with urethra sparing and organ motion control! Check it out!”
Denis Panizza, Medical Physicist at Fondazione IRCCS San Gerardo dei Tintori, also shared on X:
“3 years ago, we started enrolling, and now the preliminary results of the ABRUPT trial about single-dose prostate cancer RT have been published in the IJROBP. It was a great effort! Congratulations to the authors!”
Federica Ferrario, Radiation Oncology Resident at IRCCS San Gerardo, shared her thoughts:
“Groundbreaking! ABRUPT Trial 24Gy single-shot treatment for high-risk prostate cancer is a major success!
Median fup 18 months: no significant toxicities and exceptional tumor control.
Incredible teamwork, Stefano Arcangeli one step ahead!”
m